Literature DB >> 24807052

Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.

Cintia F M Vadesilho1, Daniela M Ferreira2, Stephen B Gordon2, David E Briles3, Adriana T Moreno1, Maria Leonor S Oliveira1, Paulo L Ho1, Eliane N Miyaji4.   

Abstract

Pneumococcal surface protein A (PspA) and pneumococcal surface protein C (PspC) are important candidates for an alternative vaccine against pneumococcal infections. Since these antigens show variability, the use of variants that do not afford broad protection may lead to the selection of vaccine escape bacteria. Epitopes capable of inducing antibodies with broad cross-reactivities should thus be the preferred antigens. In this work, experiments using peptide arrays show that most linear epitopes recognized by antibodies induced in mice against different PspAs were located at the initial 44 amino acids of the mature protein and that antibodies against these linear epitopes did not confer protection against a lethal challenge. Conversely, linear epitopes recognized by antibodies to PspC included the consensus sequences involved in the interaction with human factor H and secretory immunoglobulin A (sIgA). Since linear epitopes of PspA were not protective, larger overlapping fragments containing 100 amino acids of PspA of strain Rx1 were constructed (fragments 1 to 7, numbered from the N terminus) to permit the mapping of antibodies with conformational epitopes not represented in the peptide arrays. Antibodies from mice immunized with fragments 1, 2, 4, and 5 were capable of binding onto the surface of pneumococci and mediating protection against a lethal challenge. The fact that immunization of mice with 100-amino-acid fragments located at the more conserved N-terminal region of PspA (fragments 1 and 2) induced protection against a pneumococcal challenge indicates that the induction of antibodies against conformational epitopes present at this region may be important in strategies for inducing broad protection against pneumococci.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24807052      PMCID: PMC4097434          DOI: 10.1128/CVI.00239-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  50 in total

1.  Epitope mapping of pathogenic Leptospira LipL32.

Authors:  Javier Lottersberger; Sergio A Guerrero; Georgina G Tonarelli; Ronald Frank; Héctor Tarabla; Norma B Vanasco
Journal:  Lett Appl Microbiol       Date:  2009-08-22       Impact factor: 2.858

2.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors:  O T Avery; C M Macleod; M McCarty
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

3.  Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae.

Authors:  Q Cheng; D Finkel; M K Hostetter
Journal:  Biochemistry       Date:  2000-05-09       Impact factor: 3.162

4.  Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis.

Authors:  J Yother; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

5.  Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

Authors:  A D Ogunniyi; M C Woodrow; J T Poolman; J C Paton
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.

Authors:  Calvin C Daniels; Patricia Coan; Janice King; Joanetha Hale; Kimberly A Benton; David E Briles; Susan K Hollingshead
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

7.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

8.  Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.

Authors:  Abiodun D Ogunniyi; Marcin Grabowicz; David E Briles; Jan Cook; James C Paton
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

9.  Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Authors:  D M Ferreira; M Darrieux; D A Silva; L C C Leite; J M C Ferreira; P L Ho; E N Miyaji; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

10.  The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells.

Authors:  Sven Hammerschmidt; Vaibhav Agarwal; Anja Kunert; Steffi Haelbich; Christine Skerka; Peter F Zipfel
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

View more
  9 in total

1.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

2.  Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing Isolates.

Authors:  Taj Azarian; Lindsay R Grant; Maria Georgieva; Laura L Hammitt; Raymond Reid; Stephen D Bentley; David Goldblatt; Mathuran Santosham; Robert Weatherholtz; Paula Burbidge; Novalene Goklish; Claudette M Thompson; William P Hanage; Kate L O'Brien; Marc Lipsitch
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

3.  Streptococcus pneumoniae PspC Subgroup Prevalence in Invasive Disease and Differences in Contribution to Complement Evasion.

Authors:  Erika van der Maten; Bryan van den Broek; Marien I de Jonge; Kim J W Rensen; Marc J Eleveld; Aldert L Zomer; Amelieke J H Cremers; Gerben Ferwerda; Ronald de Groot; Jeroen D Langereis; Michiel van der Flier
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

4.  Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.

Authors:  S Glennie; J F Gritzfeld; S H Pennington; M Garner-Jones; N Coombes; M J Hopkins; C F Vadesilho; E N Miyaji; D Wang; A D Wright; A M Collins; S B Gordon; D M Ferreira
Journal:  Mucosal Immunol       Date:  2015-04-29       Impact factor: 7.313

5.  Antigenic Variation in Streptococcus pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity.

Authors:  M Georgieva; L Kagedan; Ying-Jie Lu; C M Thompson; M Lipsitch
Journal:  mBio       Date:  2018-03-13       Impact factor: 7.867

6.  Genetic diversity of pneumococcal surface protein A in invasive pneumococcal isolates from Korean children, 1991-2016.

Authors:  Ki Wook Yun; Eun Hwa Choi; Hoan Jong Lee
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

Review 7.  A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniae.

Authors:  Jessica R Lane; Muralidhar Tata; David E Briles; Carlos J Orihuela
Journal:  Front Cell Infect Microbiol       Date:  2022-02-02       Impact factor: 6.073

Review 8.  Mucosal vaccines: wisdom from now and then.

Authors:  Hiroshi Kiyono; Yoshikazu Yuki; Rika Nakahashi-Ouchida; Kohtaro Fujihashi
Journal:  Int Immunol       Date:  2021-11-25       Impact factor: 4.823

9.  The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.

Authors:  Kristopher R Genschmer; Cintia F M Vadesilho; Larry S McDaniel; Sang-Sang Park; Yvette Hale; Eliane N Miyaji; David E Briles
Journal:  mSphere       Date:  2019-12-11       Impact factor: 4.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.